Ribo Newsroom
-
First Milestone Successfully Achieved in Ribo’s Collaboration in Liver Diseases With Boehringer IngelheimFirst Milestone Successfully Achieved in Ribo’s Collaboration in Liver Diseases With Boehringer IngelheimJanuary 10, 2025 -
Ribo and Pheiron enter strategic collaboration for AI-assisted drug development of RNA therapeuticsSeptember 24, 2024 -
Ribo Presents First-In-Class FXI Targeting siRNA Drug RBD4059 Phase I Clinical Data At ESC Congress 2024Ribo Presents First-In-Class FXI Targeting siRNA Drug RBD4059 Phase I Clinical Data At ESC Congress 2024August 31, 2024 -
Innovating for a Healthier Tomorrow: Ribo Role in Transforming Liver Disease Treatment with siRNAInnovating for a Healthier Tomorrow: Ribo Role in Transforming Liver Disease Treatment with siRNA.April 8, 2024 -
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseasesBoehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseasesJanuary 3, 2024 -
Ribo and Qilu Announce Licensing Agreement for siRNA Therapeutic Targeting PCSK9Ribo and Qilu Announce Licensing Agreement for siRNA Therapeutic Targeting PCSK9December 25, 2023